• Saltar a la navegación principal
  • Saltar al contenido principal
  • Saltar al pie de página
ILAPHAR | Revista de la OFIL

ILAPHAR | Revista de la OFIL

Revista de la Organización de Farmacéuticos | Ibero-latinoamericanos | Ibero Latin American Journal of Health System Pharmacy

  • Números de la revista
  • Sobre la Revista
  • Eventos y Publicaciones

Effectiveness and safety of direct-acting antiviral agents for the treatment of hepatitis C virus infection

Barrajón Pérez L, Soler Company E, Lorente Fernández L, Pérez Pons JC

 Servicio de Farmacia. Hospital Arnau de Vilanova-Lliria. Valencia (España)

____

Rev. OFIL 2016, 26;4:243-250

Fecha de recepción: 12/08/2016  –  Fecha de aceptación: 15/09/2016

____

Correspondencia:

Laura Barrajón Pérez

Servicio de Farmacia

Hospital Arnau de Vilanova

C/San Clemente, 12

46015 Valencia

Correo electrónico: laura.barrajon@gmail.com

____

SUMMARY

Objectives: To describe and analyze patients with chronic hepatitis C treated with direct-acting antivirals and evaluate its safety and effectiveness. Secondary objectives: to identify predictive factors associated with hepatitis C antiviral therapy response; determine the appropriateness of antiretroviral therapy to avoid interactions; and to compare the results of patients with genotype 1 treated with direct-acting antivirals with historic controls treated with boceprevir or telaprevir at our institution.

Methods: 12 months, retrospective observational study, which included all patients treated with direct-acting antivirals (sofosbuvir, simeprevir, daclatasvir, ledipasvir, ombitasvir, paritaprevir, dasabuvir). Effectiveness evaluation: sustained viral response 12 weeks after treatment. Safety assessment: adverse events occurring during treatment.

Results: 355 patients were included, 50.4% cirrhotic. 345 patients were evaluable for effectiveness: 97.4% achieved sustained viral response, 2.6% failed. Subgroup analysis showed effectiveness in 98.4% of monoinfected patients vs 94.7% in patients coinfected with HIV (p=0.06); in the latter group, effectiveness was 91.7% in patients with cirrhosis vs 97.8% in patients without cirrhosis (p=0.049). Safety: 155 (43.7%) patients experienced adverse events, 9 (2.5%) of them were severe, and 3 (0.84%) needed treatment suspensions. 35 out of 97 coinfected patients needed antiretroviral therapy modification to avoid interactions (50.4% caused by simeprevir).

Conclusions: New generation of direct-acting antivirals against HCV is effective and safe in clinical practice. Our effectiveness and safety results are within the range established by major published works.

Key Words: Hepatitis C, effectiveness, safety, direct-acting antiviral agents.

____

Download full pdf: Efectividad y seguridad de los antivirales de acción directa frente al virus de la hepatitis C

Footer

Footer 1

ISSN Edición impresa: 1131-9429
ISSN Edición electrónica: 1699-714X

Web diseñada y desarrollada por Company Valor